Filetype
April 15, 2026 COMMONS annual meetingCOMMONS annual meeting program (Apr 15, 2026)The program includes: - Release event for the new edition of "The Colloidal Domain" 3rd edition (Wennerström & Evans)- A session "new and advanced methods for solving challenges in COMMONS"- Challenge poster session for exchange on ongoing work and open questions- Mingling and project discussionsCOMMONS Seminars, sp
https://www.commons-center.lu.se/seminars-and-conferences - 2026-07-03
Accessibility of commons-center.lu.seThis website is run by COMMONS Center, Division of Physical Chemistry. We want as many people as possible to be able to use this website, and this page describes how compchem.lu.se complies with the accessibility regulations, any known accessibility issues, and how you can report problems so that we can fix them.How accessible is compchem.lu.se?We know some par
https://www.commons-center.lu.se/accessibilitystatement - 2026-07-03
The COMMONS Challenges seminars foster interactive thinking and collaboration by focusing on shared principles rather than isolated details. Each seminar combines brief presentations with audience questions, small-group “beehive” sessions, and plenary discussions. Many challenges continue in focused group dialogues, aiming to spark new research projects and scientific initiatives. Ideas emerging f
https://www.commons-center.lu.se/commons-challanges - 2026-07-03
Research school activitiesWithin the COMMONS research school, we plan for 1-2 PhD courses per year. To strengthen PhD educations, we strongly encourage PhD students to attend the scientific discussions during COMMONS Challenges and seminars. We also arrange COMMONS early career workshops to strengthen network among younger scientists.PhD summer school on liquid-liquid phase separationAugust 24-26
https://www.commons-center.lu.se/research-school - 2026-07-03
2025-12-10: Nucleation at InterfacesJon Pallbo-Arvidsson & Sara Linse2025-11-24: Design a research project that engage everyone around the tableCOMMONS Early career day2025-11-19: Coarcevation and SegregationMarité Cardenas & Emma Sparr2025-04-23: LIGAND BINDINGJannette Carey (Princeton) & Ulf Ryde (LU)2025-02-21: HOW CAN CHEMISTRY BECOME BIOLOGY?George Attard (LU) & Hanna Wacklin-Knecht (ESS, LU)
https://www.commons-center.lu.se/previous-common-challenges - 2026-07-03
Seminar on the role of chemistry in science and societyA transdisciplinary seminar where toxicologist Mattias Öberg from KI presents his views on academic-industrial collaboration and the borders of science. Can chemistry be reduced to physics? Should all sciences follow the same methods? Or should each field have its own approach? Do we need a philosophy of chemistry?Chemistry has a long history
https://www.commons-center.lu.se/previous-activities - 2026-07-03
April 15 - 2026: COMMONS Annual meeting COMMONS updates: We will update on upcoming activities in COMMONS, from challenges and seminars over the research school and the early career day to the academic forum. An overview of research initiatives within COMMONS and the new related LINXS theme SMILE (Soft Matter in Life) will lead towards discussion on future plans.Advanced techniques to solve COMMON
https://www.commons-center.lu.se/previous-commons-workshops - 2026-07-03
November 24, 2025. COMMONS Early Career DayWe are thrilled to follow up on our previous announcement for COMMONS Early Career Day! This is a wonderful opportunity to connect with peers from Sweden, Denmark, and beyond in an informal and friendly setting.Date: 24th November 2025Location: The Loop, Rydbergs torg 4, LundWhy attend?• Present and discuss your ongoing projects• Talk openly about topics
https://www.commons-center.lu.se/commons-early-career-day - 2026-07-03
COMMONS seeks to bridge disciplines and reach new audiences by engaging the public in scientific discussions and connecting the natural sciences with the social sciences and humanities through its Academic Forum. Academic Forum activities include essay writing on natural science topics, public lectures and talks, and interdisciplinary seminars. Julia Ravanis is the project leader of the Academic F
https://www.commons-center.lu.se/academic-forum - 2026-07-03
CREATE Health: Translational Cancer Center CREATE Health develops and translates cutting-edge diagnostic and therapeutic innovations into real-world clinical solutions that measurably improve patient outcomes and advance public health. We combine state-of-the-art technologies, including AI-driven data analytics, next-generation sequencing, advanced molecular imaging, precision biologics and target
https://www.createhealth.lth.se/start - 2026-07-03
Centre Management Sara EkCenter Directorsara [dot] ek [at] immun [dot] lth [dot] se (sara[dot]ek[at]immun[dot]lth[dot]se) Kristina LundbergDeputy Directorkristina [dot] lundberg [at] immun [dot] lth [dot] se (kristina[dot]lundberg[at]immun[dot]lth[dot]se) Corinna RichterResearch Coordinatorcorinna [dot] richter [at] immun [dot] lth [dot] se (corinna[dot]richter[at]immun[dot]lth[dot]se) Board Carl
https://www.createhealth.lth.se/about/organisation - 2026-07-03
Collaboration, commercialisation as well as high-impact publications allow to accelerate translation of breakthrough therapies and diagnostics into clinical practice. Principle Investigators within CREATE Health have founded several spin-off companies which are already helping patients all around the world. Beside that, tens of research articles with ground-breaking discoveries have been publishe
https://www.createhealth.lth.se/impact - 2026-07-03
Var god vänta...
https://www.createhealth.lth.se/impact/publications - 2026-07-03
Open positions will be advertised on Lund University's website and on our social media channels.If you are a student and interested in doing a Master's or ExJobb project, please contact the PI of the group of interest directly.
https://www.createhealth.lth.se/about/recruitment - 2026-07-03
Links will open on the respective websites.Region SkåneMedicon VillageCHUV in LausanneTMUCI in Tianjin, ChinaOslo Cancer ClusterWorking together is an integral part of CREATE Health’s DNA. We can proudly say that CREATE Health’s researchers are highly engaged in many different collaborations and networks – too many to name all of them here. For detailed information on our researchers’ collaborativ
https://www.createhealth.lth.se/about/partners - 2026-07-03
Lead BiologicsLead Biologics was founded in 2022 by Thoas Fioretos, Carl Sandén and Marcus Järås (Lund University), Kjell Sjöström (Innovagen) and Niklas Landberg (SUS). The company combines state-of-the-art technologies with unique patient cohorts to identify multiple novel therapeutic targets in leukemias and solid tumors. The aim is to develop a first-in-class treatment against SLAMF6. A majors
https://www.createhealth.lth.se/impact/spin-companies - 2026-07-03
The Translational Cancer Faster Forward doctoral/postdoctoral programmes (2018-2025). The CanFaster programme is supported by the European Union’s Marie Skłodowska-Curie COFUND programme (Horizon 2020 framework) based on the "Mobility across borders" philosophy. The CanFaster programme has attracted international PhD and Postdoc fellows (ER) with an interest in applied medical research in oncology
https://www.createhealth.lth.se/impact/canfaster - 2026-07-03
The links below open on the respective publication website.In vivo dendritic cell reprogramming for cancer immunotherapy.Authors: Ascic, E., Catena, X., et al.Publication: Science 386, 6719Year: 2024Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab.Authors: Meng, P., Dalal, H., Chen, Y., Brueffer, C., Gladchuk, S., Alcaide, M., ... &
https://www.createhealth.lth.se/impact/canfaster/canfaster-publications - 2026-07-03
Immunotherapy has transformed the cancer treatment landscape leading to long-term responses. However, these strategies are effective in a limited number of patients and often lose their efficacy as the tumor progresses. Insufficient antigen presentation mediated by MHC downregulation and exclusion of functional antigen-presenting cells (APCs) from the tumor microenvironment (TME) are critical evas
Immuno-oncological (I-O) treatment methods have revolutionized cancer therapy and tremendous clinical benefits are achieved in some cancer patients. However, today a limited number of I-O drug targets are used and only a fraction of all cancer patients has a therapeutic response. We need to further understand the immune system in cancer in order to develop novel treatment strategies and improve su
